Gr-1+CD11b+ cells are responsible for tumor promoting effect of TGF-β in breast cancer progression

International Journal of Cancer

Volumn 131, Issue 11, 2012, Pages 2584-2595

  Li, Zhaoyang ^a   Pang, Yanli ^a   Gara, Sudheer Kumar ^a   Achyut, B R ^a   Heger, Christopher ^a   Goldsmith, Paul K ^a   Lonning, Scott ^b   Yang, Li ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b GENZYME CORPORATION   (United States)

Author keywords

biomarker; breast cancer; cells; Gr 1+CD11b+; targeted therapy; TGF

Indexed keywords

ARGINASE 1; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER GROWTH; CANCER IMMUNOTHERAPY; CELL TYPE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; FLOW CYTOMETRY; GR 1+CD11B+ CELL; IMMUNOFLUORESCENCE; MOUSE; MYELOID PROGENITOR CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SERODIAGNOSIS; SIGNAL TRANSDUCTION; SUPPRESSOR CELL; TH2 CELL; TUMOR MICROENVIRONMENT; TUMOR PROMOTION; TUMOR VOLUME;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIGENS, CD11B; APOPTOSIS; ARGINASE; CELL LINE, TUMOR; CYTOKINES; DISEASE PROGRESSION; FEMALE; LUNG; LYMPH NODES; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MYELOID CELLS; RECEPTORS, CHEMOKINE; TH2 CELLS; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKERS, BIOLOGICAL; TUMOR MICROENVIRONMENT;

EID: 84867060703     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27572     Document Type: Article

References (50)

1. Gold LI,. The role for transforming growth factor-beta (TGF-beta) in human cancer. Crit Rev Oncog 1999; 10: 303-60.
2. Elliott RL, Blobe GC,. Role of transforming growth factor Beta in human cancer. J Clin Oncol 2005; 23: 2078-93.
3. Arteaga CL,. Inhibition of TGFbeta signaling in cancer therapy. Curr Opin Genet Dev 2006; 16: 30-7.
4. Mundy GR,. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002; 2: 584-93.
5. Dumont N, Arteaga CL,. Targeting the TGF beta signaling network in human neoplasia. Cancer Cell 2003; 3: 531-6.
6. Saunier EF, Akhurst RJ,. TGF beta inhibition for cancer therapy. Curr Cancer Drug Targets 2006; 6: 565-78.
7. Yingling JM, Blanchard KL, Sawyer JS,. Development of TGF-beta signalling inhibitors for cancer therapy. Nat Rev Drug Discov 2004; 3: 1011-22.
8. Bierie B, Moses HL,. Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer 2006; 6: 506-20.
9. Derynck R, Akhurst RJ, Balmain A,. TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 2001; 29: 117-29.
10. Yang L, Moses HL,. Transforming growth factor beta: tumor suppressor or promoter? Are host immune cells the answer? Cancer Res 2008; 68: 9107-11.
11. Forrester E, Chytil A, Bierie B, et al. Effect of conditional knockout of the type II TGF-beta receptor gene in mammary epithelia on mammary gland development and polyomavirus middle T antigen induced tumor formation and metastasis. Cancer Res 2005; 65: 2296-302.
12. Guasch G, Schober M, Pasolli HA, et al. Loss of TGFbeta signaling destabilizes homeostasis and promotes squamous cell carcinomas in stratified epithelia. Cancer Cell 2007; 12: 313-27.
13. Ijichi H, Chytil A, Gorska AE, et al. Aggressive pancreatic ductal adenocarcinoma in mice caused by pancreas-specific blockade of transforming growth factor-beta signaling in cooperation with active Kras expression. Genes Dev 2006; 20: 3147-60.
14. Munoz NM, Upton M, Rojas A, et al. Transforming growth factor beta receptor type II inactivation induces the malignant transformation of intestinal neoplasms initiated by Apc mutation. Cancer Res 2006; 66: 9837-44.
15. Bhowmick NA, Chytil A, Plieth D, et al. TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 2004; 303: 848-51.
16. Bierie B, Stover DG, Abel TW, et al. Transforming growth factor-beta regulates mammary carcinoma cell survival and interaction with the adjacent microenvironment. Cancer Res 2008; 68: 1809-19.
17. Yang L, Huang J, Ren X, et al. Abrogation of TGFbeta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell 2008; 13: 23-35.
18. Flavell RA, Sanjabi S, Wrzesinski SH, et al. The polarization of immune cells in the tumour environment by TGFbeta. Nat Rev Immunol 2010; 10: 554-67.
19. Yang L, Pang Y, Moses HL,. TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression. Trends Immunol 2010; 31: 220-7.
20. Almand B, Clark JI, Nikitina E, et al. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 2001; 166: 678-89.
21. Yang L, Debusk LM, Fukuda K, et al. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 2004; 6: 409-21.
22. Gabrilovich DI, Nagaraj S,. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9: 162-74.
23. Marigo I, Dolcetti L, Serafini P, et al. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev 2008; 222: 162-79.
24. Marx J,. Cancer immunology. Cancer's bulwark against immune attack: MDS cells. Science 2008; 319: 154-6.
25. Serafini P, Borrello I, Bronte V,. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol 2006; 16: 53-65.
26. Movahedi K, Guilliams M, Van den Bossche J, et al. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T-cell suppressive activity. Blood 2008; 111: 4233-44.
27. Terabe M, Matsui S, Park JM, et al. Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J Exp Med 2003; 198: 1741-52.
28. Jessen KA, Liu SY, Tepper CG, et al. Molecular analysis of metastasis in a polyomavirus middle T mouse model: the role of osteopontin. Breast Cancer Res 2004; 6: R157-69.
29. Ljung BM, Mayall B, Lottich C, et al. Cell dissociation techniques in human breast cancer-variations in tumor cell viability and DNA ploidy. Breast Cancer Res Treat 1989; 13: 153-9.
30. Arteaga CL, Hurd SD, Winnier AR, et al. Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression. J Clin Invest 1993; 92: 2569-76.
31. Biswas S, Guix M, Rinehart C, et al. Inhibition of TGF-beta with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression. J Clin Invest 2007; 117: 1305-13.
32. Nam JS, Suchar AM, Kang MJ, et al. Bone sialoprotein mediates the tumor cell-targeted prometastatic activity of transforming growth factor beta in a mouse model of breast cancer. Cancer Res 2006; 66: 6327-35.
33. Nam JS, Terabe M, Kang MJ, et al. Transforming growth factor beta subverts the immune system into directly promoting tumor growth through interleukin-17. Cancer Res 2008; 68: 3915-23.
34. Yan HH, Pickup M, Pang Y, et al. Gr-1+CD11b+ myeloid cells tip the balance of immune protection to tumor promotion in the premetastatic lung. Cancer Res 2010; 70: 6139-49.
35. Peranzoni E, Zilio S, Marigo I, et al. Myeloid-derived suppressor cell heterogeneity and subset definition. Curr Opin Immunol 2010; 22: 238-44.
36. Youn JI, Nagaraj S, Collazo M, et al. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol 2008; 181: 5791-802.
37. Elshal MF, McCoy JP,. Multiplex bead array assays: performance evaluation and comparison of sensitivity to ELISA. Methods 2006; 38: 317-23.
38. Ostrand-Rosenberg S,. Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. Cancer Immunol Immunother 2010; 59: 1593-600.
39. Muraoka RS, Dumont N, Ritter CA, et al. Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases. J Clin Invest 2002; 109: 1551-9.
40. Yang YA, Dukhanina O, Tang B, et al. Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects. J Clin Invest 2002; 109: 1607-15.
41. Shojaei F, Wu X, Malik AK, et al. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b(+)Gr1(+) myeloid cells. Nat Biotechnol 2007; 25: 911-20.
42. Hulper P, Schulz-Schaeffer W, Dullin C, et al. Tumor localization of an anti-TGF-beta antibody and its effects on gliomas. Int J Oncol 2011; 38: 51-9.
43. Hiratsuka S, Watanabe A, Aburatani H, et al. Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat Cell Biol 2006; 8: 1369-75.
44. Fridlender ZG, Sun J, Kim S, et al. Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN. Cancer Cell 2009; 16: 183-94.
45. Lee GT, Hong JH, Kwak C, et al. Effect of dominant negative transforming growth factor-beta receptor type II on cytotoxic activity of RAW 264.7, a murine macrophage cell line. Cancer Res 2007; 67: 6717-24.
46. Nam JS, Terabe M, Mamura M, et al. An anti-transforming growth factor beta antibody suppresses metastasis via cooperative effects on multiple cell compartments. Cancer Res 2008; 68: 3835-43.
47. Terabe M, Ambrosino E, Takaku S, et al. Synergistic enhancement of CD8+ T cell-mediated tumor vaccine efficacy by an anti-transforming growth factor-beta monoclonal antibody. Clin Cancer Res 2009; 15: 6560-9.
48. Almand B, Resser JR, Lindman B, et al. Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res 2000; 6: 1755-66.
49. Budhu A, Forgues M, Ye QH, et al. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell 2006; 10: 99-111.
50. Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313: 1960-4.